Iovance Biotherapeutics, Inc. Common Stock
IOVA Real Time Price USDRecent trades of IOVA by members of U.S. Congress
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by IOVA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$260,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
-
$260,000 Oct 11, 2022 Issue: Medicare/Medicaid Health Issues
-
$260,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$50,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$50,000 Apr 19, 2022 Issue: Health Issues
-
$50,000 Jan 20, 2022 Issue: Health Issues
-
$50,000 Jan 19, 2022 Issue: Medicare/Medicaid
-
$50,000 Oct 20, 2021 Issue: Medicare/Medicaid
-
$50,000 Oct 20, 2021 Issue: Health Issues
-
$50,000 Jul 20, 2021 Issue: Medicare/Medicaid
-
$50,000 Jul 19, 2021 Issue: Health Issues
-
$40,000 Apr 20, 2021 Issue: Medicare/Medicaid
-
$40,000 Apr 19, 2021 Issue: Health Issues
-
$30,000 Jan 21, 2021 Issue: Medicare/Medicaid
-
$30,000 Jan 19, 2021 Issue: Health Issues
Estimated quarterly lobbying spending
IOVA Revenue by Segment or Geography
New patents grants
-
Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Feb. 25, 2025
-
Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Feb. 18, 2025
-
Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Feb. 18, 2025
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 18, 2025
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 14, 2025
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 07, 2025
-
Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Dec. 17, 2024
-
Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Dec. 03, 2024
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Oct. 22, 2024
-
Patent Title: Processes for generating til products enriched for tumor antigen-specific t-cells Oct. 01, 2024
-
Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 09, 2024
-
Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 02, 2024
-
Patent Title: Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof Jul. 02, 2024
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jun. 04, 2024
-
Patent Title: Til expansion processes using specific cytokine combinations and/or akti treatment May. 14, 2024
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 07, 2024
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 30, 2024
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 26, 2024
-
Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 09, 2024
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 09, 2024
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 02, 2024
-
Patent Title: Methods of using tumor infiltrating lymphocytes in double-refractory melanoma Nov. 21, 2023
-
Patent Title: Processes for generating til products enriched for tumor antigen-specific t-cells Aug. 01, 2023
-
Patent Title: Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion Jun. 06, 2023
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 16, 2023
-
Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Apr. 18, 2023
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 03, 2023
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 20, 2022
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 06, 2022
-
Patent Title: Methods of using tumor infiltrating lymphocytes in double-refractory melanoma Sep. 06, 2022
-
Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Aug. 02, 2022
-
Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 12, 2022
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 28, 2022
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 21, 2022
-
Patent Title: Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof Jun. 14, 2022
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 07, 2022
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 07, 2022
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 31, 2022
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 31, 2022
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 31, 2022
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 24, 2022
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 26, 2022
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 19, 2022
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 19, 2022
-
Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Apr. 05, 2022
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 05, 2022
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 15, 2022
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 15, 2022
-
Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Mar. 08, 2022
-
Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 22, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to IOVA
Recent picks made for IOVA stock on CNBC
ETFs with the largest estimated holdings in IOVA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
---|
- Is $IOVA stock a Buy, Sell, or Hold?
- What is the price target for $IOVA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
Shareholder
|
Shares Held
|
---|
- Who owns $IOVA stock?
- Who owns the most shares of $IOVA stock?
- What funds own $IOVA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IOVA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.